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Abstract  
Background The number of elderly patients with chronic kidney disease (CKD) Stage 5 is steadily 
increasing. Evidence is needed to inform decision-making for or against dialysis, especially in those patients 
with multiple co-morbid conditions for whom dialysis may not increase survival. We therefore compared 
survival of elderly patients with CKD stage 5 managed either with dialysis or conservatively (without 
dialysis), after the management decision had been made, and explored which of several key variables were 
independently associated with survival. 
Methods A retrospective analysis of the survival of all patients over 75 years with CKD Stage 5 attending 
dedicated multidisciplinary pre-dialysis care clinics (n=129) was performed. Demographic and co-morbidity 
data was collected on all patients. Survival was defined as the time from estimated GFR<15 ml/minute to 
either death or study endpoint. 
Results One and two-year survival rates were 76% and 71% in the dialysis group (n = 52) and 46% and 35% 
in the conservative group (n = 77), with significantly different cumulative survival (log rank 13·6 p < 0·001). 
However, this survival advantage was lost in those patients with high co-morbidity scores, especially when 
the co-morbidity included ischaemic heart disease. 
Conclusions In CKD Stage 5 patients over 75 years who receive specialist nephrological care early, and who 
follow a planned management pathway, the survival advantage of dialysis is substantially reduced by co-
morbidity, and ischaemic heart disease in particular. Co-morbidity should be a major consideration when 
advising elderly patients for or against dialysis.  
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Introduction 
 The annual acceptance rate for renal replacement therapy (RRT) in the UK is rising steadily, from 20 
per million population (pmp) in the 1980s to 103 pmp in 2004 1,2. Reasons for this include increased referral 
rates, increased availability/resources, and improved ability to treat. Old age is no longer seen as an absolute 
contraindication to dialysis. Between 1998 and 2004, the percentage of incident patients aged over 75 had 
risen from approximately 18% to 23% in England, and from 20% to 29% in Wales 2 A strong relationship 
between increasing age and rising CKD prevalence has been reported, 3,4
 
The number of elderly patients with 
CKD Stage 5 is projected to increase considerably in coming years.5 This is partly due to changes in 
population age demographics 6, particularly in ethnic minorities, and the increasing prevalence of Type II 
diabetes mellitus 7, but also due to increased recognition and referral of CKD. 
 For each patient, the decision to commence dialysis or to have conservative management (without 
dialysis) is complex. It is important to recognize that conservative management (without dialysis) is not 
simply defined by the absence of dialysis provision: it entails active disease management (for example, 
active treatment of anaemia), and detailed supportive care, which often becomes increasingly complex 
towards the end of life. Prognosis, anticipated quality of life (with or without dialysis), treatment burden (if 
dialysis is undertaken), and patient preferences, all play a part in the decision for or against dialysis. The 
decision becomes increasingly challenging in older patients,8 not because age itself precludes dialysis, but 
because considerations of co-morbidity, reduced overall lifespan, and the impact of dialysis itself on quality 
of life, become more complex with increasing age. Factors influencing the decision, such as length of 
survival,9-14 determinants of survival,12,15-18 quality of life,9,12,19-22 and disease burden,12 have all been studied 
in older dialysis patients, but there is little comparative data on survival once the decision has been made. 
This study intends therefore, not to elucidate the factors influencing the dialysis decision-making, but instead 
to evaluate survival once the decision for or against dialysis has been made. The aims of this study were 
therefore to describe and compare survival, once the dialysis decision has been made, in CKD patients over 
75 years managed with dialysis and those managed conservatively, and to identify which of several key 
variables might be independently associated with survival. 
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Subjects and Methods 
 Clinical databases at four major renal units in the South Thames Region were searched for all 
patients > 75 years receiving dedicated multidisciplinary pre-dialysis care, during a twelve month period 
(from 1st Sept 2003 to 31st Aug 2004), and who had chosen either dialysis or conservative management. 
Dedicated multidisciplinary pre-dialysis care is provided by a team of physicians, specialist nurses, 
counsellors and dieticians, providing additional educational, dietary, social and psychological support to that 
available in the general clinic. Within all four units, all patients predicted to need dialysis within eighteen 
months are directed from general nephrology care into this dedicated multidisciplinary pre-dialysis care. This 
excludes patients presenting late with previously undiagnosed CKD or in who a rapid unforeseen 
deterioration in function has occurred, who are seen within the general nephrology clinics, and for whom 
dialytic therapy tends to be the default option. The main difference between dedicated multi-disciplinary pre-
dialysis care and general nephrology care is the time and resources available for education and psycho-social 
support, and the level of decision making support provided in anticipation of reaching end-stage renal 
disease. Classification into dialysis or conservative management was based on planned pathway, and analysis 
was therefore on an ‘intention to treat’ basis. Those following the conservative pathway continued to receive 
dedicated multidisciplinary nephrological care.  
 
The final decision about dialysis was made jointly between each patient and their nephrologist, based on the 
patient’s wishes and suitability for dialysis. The decision for or against dialysis was determined by the 
anticipated benefit/burden of receiving dialysis, with particular consideration of quality of life and expected 
survival on or off dialysis. These (largely unknown) factors are discussed with the patient (and family, 
according to the patient’s wishes for family involvement), with the emphasis on shared decision-making, 
unless the patient expressly chooses to hand the decision to their nephrologist (an infrequent occurrence). 
The decision for or against dialysis is therefore usually made together with the patient, according to their 
preferences and in the light of best estimation of these factors. No patient who wishes to have dialysis is 
denied this treatment option, though most with very limited prognosis (such as advanced progressive 
metastatic cancer for which treatment options are exhausted) choose not to have dialytic therapy.  Whe
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dialytic therapy might be deemed inappropriate on the grounds of severe co-morbidity, the patient would be 
appraised of the likely difficulties and complications relating to therapy, and the likely lack of benefit, but 
treatment would not be refused if the individual so wished.  Where patients do not have the capacity to make 
a decision, a judgement on suitability for dialysis is undertaken by the medical professional in conjunction 
with the patient’s advocate, based on perceived improvement in quality of life and ability to co-operate with 
treatment.  
 Estimated glomerular filtration rate (eGFR) was calculated using the six-point Modification of Diet 
in Renal Disease formula.23 Patients presenting to nephrology services with eGFR already <15ml/min, and 
those with incurable solid organ malignancy were excluded. Data was collected on: age, sex, ethnicity, 
primary renal diagnosis, renal unit, co-morbidity score and individual co-morbid factors. Ethnicity and 
primary renal diagnosis were categorised according to Renal Registry categories.2 Co-morbidity was scored 
according to the system devised by Davies et al, and graded as low (0), medium (1) or high (2).18 Data for the 
individual co-morbid factors used to derive the score were also collected. For each eligible patient, the date 
when eGFR was first <15ml/min was identified. The study endpoint was 30th June 2005, and it was noted 
whether each patient was still alive on, or had died before, this date. For those who had died, date of death 
was recorded. Survival was calculated from the date when eGFR was first <15ml/min until death (or end of 
study if still alive). 
 Descriptive statistics are presented for dialysis and conservative groups. χ2 and Mann Whitney U 
tests were used to test for differences between the two groups. Kaplan-Meier and log rank test methods were 
used to estimate and compare survival. Cox proportional hazard regression models were used to investigate 
the impact of independent variables on survival. Exploratory analysis of the relationship between each single 
variable and the dependent variable (survival) was carried out, using age, sex, ethnicity, renal diagnosis, co-
morbidity score, individual co-morbidity factors, renal unit, and treatment modality (dialysis or 
conservative), in turn. The independent variables most strongly associated with survival (p values below or 
close to 0·05) were used in Cox multiple regression analysis to estimate their independent impact on 
survival. Statistical analyses were performed using SPSS version 12. 
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Results 
 129 patients (52 dialysis and 77 conservatively-managed) fulfilled the inclusion criteria. Complete 
information was obtained for all patients, with no missing data. 24 patients who chose the dialysis pathway 
did not actually received dialysis during the study period, either because they died unexpectedly before 
dialysis began (n=8), or because dialysis had not started by study end (n=16) (see Figure 1). The mean eGFR 
at dialysis start for those who did start dialysis was 8.1 ml/minute. Demographic data, renal diagnosis and 
co-morbidity score are illustrated in Table 1. With the exception of age, statistical comparison did not 
provide evidence of difference between the two groups. The conservatively managed patients were older 
(median age of 83·0 years), compared to dialysis patients (median age 79·6 years (p<0·001)). The two groups 
were comparable in co-morbidity scores, despite the known clinical weight given to co-morbidity in the 
dialysis decision-making process. Median time from when eGFR was first 15 ml/min to death or study end 
was 588 days (range 67-2528 days) for those patients on dialysis, and 540 days (range 4 – 2193 days) for 
those managed conservatively. 
 Of the total of 129 patients in the study, 63 (48·8%) died before the end of the study; 12 from the 
dialysis group (23% of all dialysis patients) and 51 from the conservative group (66% of all conservative 
patients) (see Figure 1). We were unable to ascertain cause of death sufficiently accurately to provide 
meaningful data for comparison, particularly in the conservative group, where the majority of deaths 
occurred in the community. Table 2 shows the one and two-year survival rates according to treatment choice. 
The superior survival rate of those patients opting for dialysis is further illustrated in Figure 2, which 
compares overall survival between the two groups (log rank statistic = 13·63, p < 0·001). However, as the 
decision for or against dialysis is particularly challenging in those with high co-morbidity, survival was also 
compared between the dialysis and conservative groups for patients with a co-morbidity grade of 2. For 
patients with high co-morbidity, the survival advantage offered by dialysis is no longer apparent, as shown in 
Figure 3 (log rank statistic < 0·001, df 1, p = 0·98).  
 The impact of the various factors studied on survival was analysed using Cox regression. Initial Cox 
regression analysis (using each explanatory variable in turn) identified modality choice (regression 
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coefficient B = -1·128, p < 0·001), age (regression coefficient B = 0·061, p = 0·028), and co-morbidity as 
being the most strongly associated with survival. With respect to co-morbidity, both overall co-morbidity 
score (regression coefficient B = 0·408, p = 0·081) and ischaemic heart disease alone (regression coefficient 
B = -0·678, p = 0·009) were associated with survival, ischaemic heart disease more strongly than overall co-
morbidity score. No association with survival was seen for the other variables analysed (renal unit, sex, 
ethnicity, primary renal diagnosis, and the remaining co-morbid factors used to construct the Davies co-
morbidity score). Accordingly, modality, age, overall co-morbidity score and ischaemic heart disease were 
fitted to a Cox regression model, to estimate the independent effect of each. Age and overall co-morbidity 
score did not achieve significance at the 5% level, and were therefore removed from the final model. The 
hazard ratios generated indicate that, in our study, modality and ischaemic heart disease were the most 
important variables. The regression coefficients, associated p-values, hazard ratios and confidence intervals 
are shown in Table 3. In the final model, patients who chose dialysis had a better survival (2·9-fold), whereas 
having ischaemic heart disease reduces survival by just less than half. 
 Because of the strength of association between ischaemic heart disease and survival identified, this 
relationship was analysed further. Figures 4a and 4b show the survival curves for patients with and without 
ischaemic heart disease, again comparing the dialysis and conservative groups. In patients with ischaemic 
heart disease there is no evidence that a decision to follow a dialysis pathway results in an improvement in 
survival. 
 
Discussion 
 In this study patients aged over 75 years who chose dialysis had improved survival compared to 
those who chose conservative management. However the study indicates that this survival advantage is lost 
in those with high co-morbidity scores, particularly those with ischaemic heart disease. With elderly patients, 
co-morbidity (especially the presence of ischaemic heart disease) should therefore be a key consideration in 
the dialysis decision-making process. This study does not attempt to elucidate the complex process of how 
and why different dialysis decisions are made. Instead, it describes survival once the decision has been made.  
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 Our findings concur with the conclusions drawn by Smith et al in their evaluation of non-dialytic 
management,13 and adds to the evidence informing dialysis decision making in elderly patients with CKD, 
particularly those with high co-morbidity scores. In patients with significant co-morbidity, clinicians need to 
consider whether dialysis offers sufficient survival benefit for it to be a standard treatment or whether non-
dialytic management may offer comparable survival without the treatment burden of dialysis. For those who 
chose dialysis in the study, we do not know how much of the survival benefit is due to the treatment 
modality itself, and how much reflects bias introduced by the selection process itself. Those choosing 
dialysis may be more likely to survive because of better physical status or other unknown factors which are 
positively associated both with survival and with the decision to have dialysis. It is likely that the factors 
characterizing these two groups are more complex than can be identified by simple demographic 
comparators. The retrospective nature of this study did not allow performance score or other indicators of 
physical status to be collected, although this is an importance consideration for future prospective work. It is 
worth noting that the demographic comparison identified only age as significantly different. Perhaps most 
surprisingly, we identified no difference in co-morbidity between the two groups. This is in keeping with 
data published by Joly et al,14 though Smith et al identified highly significant differences in co-morbidity 
between those opting for dialysis and those choosing conservative management.13 These differences may be 
attributable to the older age in both our study (>75 years) and that by Joly (>80 years), compared with all 
ages in the study by Smith et al. Co-morbidity may discriminate between the groups less well in older 
patients, since levels of co-morbidity are uniformly high. 
 Evidence on the factors which influence dialysis decision-making is limited, and much of this relates 
to decisions on withdrawal of dialysis, rather than decisions on not starting it. A clinical judgement analysis 
undertaken by Kee and colleagues24 suggests that the extent to which individual nephrologists vary in their 
propensity to offer dialysis is considerable. The same study also identified mental state as one of the most 
important considerations in the decision24. RPA/RSN guidelines from the USA stress the importance of 
shared decision-making25. Shared decision-making requires the patient to be informed, and as Moss points 
out, although individual factors (such as age, nutritional status and functional status) are known to be 
powerful predictors of prognosis, there is no reliable way to combine these into an overall prognostic 
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indicator to guide the individual patient and nephrologist25. Dealing with this uncertainty may account for 
some of the variations in dialysis decision-making, but also makes it difficult to measure or standardize 
dialysis decisions for comparative purposes in research.  
 A limitation of this study therefore is that these survival findings may not be generalizable to other 
settings if dialysis decision-making differs considerably in those settings from that undertaken in the study 
units – dialysis decision-making, as already indicated, is known to vary considerably between units and even 
between individual nephrologists 24. It is important to note that demographic and survival comparisons 
between the four units did not uncover any surprising differences, within the constraints of the small 
numbers studied. We recognize that a high overall percentage of patients elected conservative management; 
these numbers have increased in the UK recently, but are not yet recorded nationally by the UK Renal 
Registry or by other national registries such as the US Renal Data System26. The numbers in this study are 
comparable with other renal units in the UK 13, although the percentage choosing conservative 
management reported here does not reflect overall dialysis acceptance in elderly patients, since 
dialysis may predominate in those who present late and are not included in this analysis. It is notable 
that no patients on the conservative pathway in this study switched to dialysis, although they had this 
opportunity – this may reflect the level of decision making support provided by the multi-disciplinary team 
approach, or possibly the older age of this study population; younger patients may be more likely to switch 
as symptoms ensue, but there is little evidence on factors which influence switch. 
 There are other considerations for our study. First, the study deliberately considered patients who 
were in specialist care at a point when their eGFR fell below 15ml/min. We made this decision in order to 
avoid the bias introduced by those presenting late - similar conclusions cannot be drawn for patients 
presenting much later in their disease course, perhaps requiring more immediate dialysis treatment.. Late 
referrals are more common in the elderly, and may represent up to 60% of elderly patients presenting with 
established renal failure27. We recognize the need for evidence in this late presenting or acute population, but 
it is clear that patients who receive early high quality care and have time to plan optimum management are 
likely to have better outcomes, both in the dialysis and conservative groups. In this study we have 
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deliberately focused on the group with optimal pre-dialysis care, because a separate study avoids the need to 
disentangle the potential bias when both populations are studied together.  
 In addition, although the overall numbers (129 patients) were considerable for a study of this type, 
where study entry was restricted to elderly patients with a planned management pathway, in statistical terms 
numbers were relatively small. Likewise, the number of deaths, particularly in the dialysis group, was small 
for statistical purposes, especially when patients with high co-morbidity or ischaemic heart disease alone 
were considered. This limited the number of variables that could be evaluated and for this reason we focused 
on those described as important in the literature. It would have also been useful to establish the cause of 
death, in order to determine the proportions in each group in which death could be attributable to the renal 
disease – this is however, difficult to ascertain reliably 28, 29, and may not for this reason have aided the 
comparison of the two groups. Despite these limitations, in patients with high comorbidity, the absence of a 
survival difference between patients opting for dialysis and those who chose conservative management is 
striking. There has been very little comparison of survival between these two groups in the literature to date, 
and this study underlines the need for further research on survival of conservatively-managed patients. 
Prospective survival studies, incorporating greater numbers of patients are urgently needed, as are studies 
exploring the reasons underlying dialysis decision-making, from both patient and professional perspectives. 
 There is considerable evidence on survival in elderly dialysis patients, although survival is usually 
measured from dialysis commencement rather than from eGFR 15ml/min (as in this study), making 
comparisons difficult. Median survival time has not been calculated in our study because of the low death 
rate in the dialysis group, which would make a calculated median survival time very imprecise30. Munshi et 
al, in a group of dialysis patients over 75 years, identified one and five-year survival rates of 53·5%, and 
2·4% respectively, measured from start of dialysis11. Lamping and colleagues also measured survival in 
dialysis patients over 70 years old, in the North Thames Dialysis Study, and reported one-year survival rates 
of 71%,12 which are only slightly less than that we identified (76%). Survival rates calculated from the start 
of dialysis may not account for variations in timing of dialysis initiation, particularly those consequent on 
late nephrology referral which may be more common in the elderly, and which were excluded from our 
study. 
 11 
 In our experience, elderly patients considering conservative management frequently ask what their 
estimated survival without dialysis might be. Existing literature is limited, and focuses on survival from the 
point of dialysis or putative dialysis, and it can be difficult to estimate when this time point might occur. 
Smith and colleagues report median survival times for both dialysed-palliative (recommended for the 
conservative pathway but preferred dialysis) and non-dialysed (recommended for the conservative pathway 
and agreed not to have dialysis) palliative patients of all ages of 8·3 and 6·3 months respectively, but 
relatively small numbers in these groups (n=10 and 26) make definitive conclusions difficult.13 Survival was 
measured from dialysis initiation or ‘putative dialysis initiation’ for those managed without dialysis, with a 
reported mean eGFR of 8·9 and 9·4 ml/min at onset of dialysis or ‘putative dialysis’. Joly and colleagues 
followed 107 dialysis, and 37 conservatively-managed patients, aged 80 years plus, for over 12 years.14 
Survival was measured from eGFR <10ml/min, and consequently one- and two-year survival rates of 73·6% 
and 60·0% (in the dialysis group), 29% and 15% (in the conservative group) are considerably less than we 
identified. Joly et al also included late referrals (excluded from our study), which differentially biased 
(reduced) survival times in the conservative group. Kurella et al used data from the US Renal Data System to 
report that survival rates for octagenarians and nonagenarians starting dialysis in the US were substantially 
lower than those previously reported, but were unable to report survival for conservatively-managed patients 
because the USRDS does not collect data on patients from whom dialysis is withheld 26. To the best of our 
knowledge, our study is the first that attempts to describe survival from eGFR 15mls/min in patients opting 
for conservative management, a clinically relevant time point as discussions regarding dialysis (or not) are 
often in progress at this stage, at least for those patients receiving dedicated pre-dialysis care.  
 For patients over 75 years with CKD stage 5 who are referred to nephrology care early, and who 
follow a planned management pathway, those choosing to follow a dialysis pathway have a survival 
advantage. It is not clear whether this survival advantage derives from dialysis itself or from the selection of 
patients into this management pathway, but nevertheless, co-morbidity, and ischaemic heart disease in 
particular, appear to substantially reduce this survival advantage. Co-morbidity should therefore be one of 
the main considerations when advising elderly patients for or against dialysis, although further research is 
needed to clarify and confirm this. Future prospective survival studies should measure eGFR in both dialysis 
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and conservative groups regularly, so as to compare survival at different levels of disease severity, and 
additional work is needed to explore the determinants of the dialysis decision, from both nephrology and 
patient perspectives. For those patients with high co-morbidity including ischaemic heart disease, 
conservative management should be considered. Conservative management does not imply ‘not for care’, but 
rather active disease management and detailed supportive care right up until the end of life. 
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Table 1: Patient Demographic Data 
 Dialysis  
group 
n = 52 
Conservative 
group 
n = 77 
All patients 
 
n = 129 
Statistic  
(comparing dialysis and 
conservative groups) 
Age in years (%): 
75 - 79 
80 - 84 
85 – 89 
> 89 
Total 
 
24 (46·2) 
23 (44·2) 
5 (9·6) 
0 (0·0) 
52 (100·0) 
 
12 (15·5) 
36 (46·8) 
24 (31·2) 
5 (6·5) 
77 (100·0) 
 
36 (27·9) 
59 (45·7) 
29 (22·5) 
5 (3·9) 
129 (100·0) 
 
Mann Whitney U = 
1005·00 a 
p<0·001 
 
Sex (%): 
male 
female 
Total 
 
34 (65·4) 
18 (34·6) 
52 (100·0) 
 
51 (66·2) 
26 (33·8) 
77 (100·0) 
 
85 (65·9) 
44 (34·1) 
129 (100·0) 
 
χ
2 
= 0·010 
p= 0·92 
df 1 
Ethnicity (%): 
Asian 
Black 
Chinese 
White 
Other 
Total 
 
3 (5·7) 
7 (13·5) 
0 (0·0) 
42 (80·8) 
0 (0·0) 
52 (100·0) 
 
4 (5·2) 
7 (9·1) 
0 (0·0) 
65 (84·4) 
1 (1·3) 
77 (100·0) 
 
7 (5·4) 
14 (10·9) 
0 (0·0) 
107 (82·9) 
1 (0·8) 
129 (100·0) 
 
χ
2 
= 1·290 
p= 0·73 
df 3 
Renal diagnosis (%): 
Aetiology uncertain 
Glomerulonephritis 
Pyelonephritis 
Diabetes mellitus 
Renovascular disease 
Hypertension 
Polycystic kidneys 
Other 
Total 
 
12 (23·1) 
2 (3·8) 
2 (3·8) 
13 (25·0) 
7 (13·4) 
4 (7·7) 
1 (1·9) 
11  (22·1) 
52 (100·0) 
 
27 (35·0) 
2 (2·6) 
1 (1·3) 
18 (23·4) 
14 (18·2) 
0 (0·0) 
1 (1·3) 
14 (18·2) 
77 (100·0) 
 
39 (30·2) 
4 (3·1) 
3 (2·3) 
31 (24·0) 
21 (16·3) 
4 (3·1) 
2 (1·6) 
25 (19·4) 
129 (100·0) 
 
χ
2 
= 9·099 
p= 0·25 
df 7 
Co-morbidity score: 
Grade 0 
Grade 1 
Grade 2 
Total 
 
8 (15·4) 
34 (65·4) 
10 (19·2) 
52 (100·0) 
 
10 (13·0) 
53 (68·8) 
14 (18·2) 
77 (100·0) 
 
18 (14·0) 
87 (67·4) 
24 (18·6) 
129 (100·0) 
 
χ
2 
= 0·201 
p=0·90 
df 2 
a 
Using age by year not by 5-yr categorized age, although 5-yr categorized age is displayed in the table for simplicity 
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Table 2: One- and two-year survival rates  
 Dialysis group Conservative group All patients 
1 year survival rate 75·7 % 46·5 % 57·5 % 
2 year survival rate 70·8 % 35·4 % 48·1 % 
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Table 3: Statistics from the Cox regression analysis using the variables of 
modality and ischaemic heart disease 
 
Variable coefficient (B) 
(log hazard 
function) 
P value exp(B) 
(hazard 
ratio) 
95% CI for exp(B) 
Modality 1·077 0·001 2·937 1·560 – 5·531 
Ischaemic heart disease -0·590 0·023 0·554 0·333 – 0·923 
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Figure Legends 
 
Figure 1: Flow diagram of study participants and outcomes. 
 
Figure 2: Kaplan-Meier survival curves comparing the dialysis and conservative 
groups (log rank statistic = 13·63, p < 0·001). 
 
Figure 3: Kaplan-Meier survival curves for those with high co-morbidity (score = 2), 
comparing dialysis and conservative groups (log rank statistic < 0·001, df 1, p = 0·98). 
 
Figure 4a: Kaplan-Meier survival curves for those with ischaemic heart disease, 
comparing the dialysis and conservative groups (log rank statistic 1·46, df 1, p = 
0·27). 
 
Figure 4b: Kaplan-Meier survival curves for those without ischaemic heart disease, 
comparing the dialysis and conservative groups (log rank statistic 12.78, df 1, p 
<0.0001). 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4a 
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Figure 4b 
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